Late this afternoon the FDA approved the G6 system from Dexcom (NASDAQ: DXCM). Per a company issued press release;
“DexCom, Inc. (NASDAQ: DXCM), the leader in continuous glucose monitoring (CGM) is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted a De Novo request for the Dexcom G6® CGM System, the newest generation of CGM for people with diabetes ages 2 and up. The Dexcom G6 is indicated by the FDA for use as both a standalone CGM and for integration into automated insulin dosing (AID) systems. The powerful and revolutionary new Dexcom G6® is . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.